Journal of Clinical Oncology, Vol 9, 1314-1319, Copyright © 1991 by American Society of Clinical Oncology
Marijuana as antiemetic medicine: a survey of oncologists' experiences and attitudes
RE Doblin and MA Kleiman
Kennedy School of Government, Cambridge, MA 02138.
A random-sample, anonymous survey of the members of the American Society of
Clinical Oncology (ASCO) was conducted in spring 1990 measuring the
attitudes and experiences of American oncologists concerning the antiemetic
use of marijuana in cancer chemotherapy patients. The survey was mailed to
about one third (N = 2,430) of all United States-based ASCO members and
yielded a response rate of 43% (1,035). More than 44% of the respondents
report recommending the (illegal) use of marijuana for the control of
emesis to at least one cancer chemotherapy patient. Almost one half (48%)
would prescribe marijuana to some of their patients if it were legal. As a
group, respondents considered smoked marijuana to be somewhat more
effective than the legally available oral synthetic dronabinol ([THC]
Marinol; Unimed, Somerville, NJ) and roughly as safe. Of the respondents
who expressed an opinion, a majority (54%) thought marijuana should be
available by prescription. These results bear on the question of whether
marijuana has a "currently accepted medical use," at issue in an ongoing
administrative and legal dispute concerning whether marijuana in smoked
form should be available by prescription along with synthetic THC in oral
form. This survey demonstrates that oncologists' experience with the
medical use of marijuana is more extensive, and their opinions of it are
more favorable, than the regulatory authorities appear to have believed.